IMMX (Immix Biopharma) Float Percentage Of Total Shares Outstanding : 59.14% (As of Jul. 22, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Immix Biopharma Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Immix Biopharma's float shares is 16.49 Mil. Immix Biopharma's total shares outstanding is 27.88 Mil. Immix Biopharma's float percentage of total shares outstanding is 59.14%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Immix Biopharma's Insider Ownership is 12.51%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Immix Biopharma's Institutional Ownership is 10.47%.

Immix Biopharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Immix Biopharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	16.49	/	27.88
	=	59.14%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immix Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immix Biopharma Inc (NAS:IMMX) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

11400 West Olympic Boulevard, Suite 200, Los Angeles, CA, USA, 90064

Website

https://www.immixbio.com

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Executives

Jason Hsu	director	11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Carey Ng	director	11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Ilya M Rachman	director, officer: CEO and Chairman	11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Gabriel S Morris	director, officer: Chief Financial Officer	11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Helen C. Adams	director	15378 AVENUE OF SCIENCE, STE 100, SAN DIEGO CA 92128
Melissa Jane Buchan	director	1920 MAIN STREET, SUITE 500, IRVINE CA 92614
Magda Marquet	director	ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
Yekaterina Chudnovsky	director, 10 percent owner	C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Sean Senn	10 percent owner	11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Vladimir P Torchilin	officer: Scientific Co-Founder	11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Graham Ross	officer: CMO & Head of Clinical Dev.	11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064